1.Preparation of 125I-Iodotyraminehemisuccinyltaxol ( 125ITHT ) for Competitive Taxol Radioimmunoassay.
Chang Woon CHOI ; Sang Moo LIM ; Ok Doo AWH ; Tae Sup LEE ; Tae Hyun CHOI ; Hyun Suk KIM ; Jun Pyo HONG ; Eun Sook LEE
Korean Journal of Nuclear Medicine 2002;36(2):121-132
No abstract available.
Paclitaxel*
;
Radioimmunoassay*
2.Radiation Recall Dermatitis after Treatment with Paclitaxel and Cisplatin.
Seung Woo BAEK ; Young Joon SEO ; Jun Sang KIM ; Hyo Jin LEE
Annals of Dermatology 2012;24(2):223-224
No abstract available.
Cisplatin
;
Paclitaxel
;
Radiodermatitis
3.Characterization of purified coconut oil bodies as an encapsulating agent for Doxorubicin and Paclitaxel
Pamela T. Aliman ; Ronina Franne N. Cada ; Mark Kevin P. Devanadera ; Alexis M. Labrador ; Myla R. Santiago-Bautista
Acta Medica Philippina 2021;55(4):442-450
Introduction:
Doxorubicin (DOX) and paclitaxel (PTX) are both widely used anticancer drugs with a broad spectrum of antitumor activity, commonly against breast, ovarian, and lung cancers. Currently, these drugs are commercially available in liposomal formulations for their use in chemotherapy. This study generally proposed coconut oil bodies (COB) obtained from Cocos nucifera L. as an alternative carrier for DOX and PTX rather than the currently used liposome.
Objectives:
This study aimed to compare standard liposome and coconut oil bodies as drug carriers in terms of their microencapsulation efficiencies, lipid profiles, in vitro drug release and stability, as well as their cholesterol levels.
Methods:
Coconut oil bodies (COB) were isolated and purified from Cocos nucifera L. by modified sucrose
gradient method followed by microencapsulation of standard drugs (doxorubicin and paclitaxel) through selfassembly and freeze-thaw method. The two standard drugs were encapsulated using COB and standard liposome. Encapsulation efficiency of both materials were determined. Lipid profiles of both encapsulating materials were analyzed by Fourier-transform infrared spectroscopy, gas chromatography-flame ionization detector, and cholesterol level determination. In vitro drug release and pH stability of both encapsulated drugs were analyzed.
Results:
Doxorubicin (DOX) and paclitaxel (PTX) were successfully incorporated in COB. Lauric acid was mainly
abundant in COB and was able to lower cholesterol levels (5 mg/dL). COB incorporated with DOX and PTX
showed stability at acidic and neutral pH. Drug release profile showed a rapid outburst within 3 hours compared to liposome encapsulated DOX and PTX.
Conclusion
Our study showed the encouraging potentials of using COB as wall materials that will make them
attractive candidates for the formulation of pharmaceuticals for optimized drug delivery of cancer chemotherapeutics DOX and PTX
Liposomes
;
Doxorubicin
;
Paclitaxel
4.Phase II Study of Cisplatin, Ifosfamide . Paclitaxel (CIP) as Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Carcinoma.
Seog Beom YOON ; Jong Kug LEE ; Seob JEON ; Ji Yeon LEE ; Seung Do CHOI ; Dong Han BAE
Korean Journal of Obstetrics and Gynecology 2000;43(10):1763-1768
No abstract available.
Cisplatin*
;
Drug Therapy*
;
Humans
;
Ifosfamide*
;
Paclitaxel*
5.Treatment of Disseminated Classic Type of Kaposi's Sarcoma with Paclitaxel.
Soo Yeon KIM ; Dae Hoon KIM ; Hyo Jin LEE ; Young Joon SEO ; Jeung Hoon LEE ; Young LEE
Annals of Dermatology 2011;23(4):504-507
Classic Kaposi sarcoma (KS) is a rare human herpes virus 8-associated angioproliferative disease, and the disseminated classic type of KS in Korea is even rarer. The treatment options for classic KS vary and range from surgical excision to ionizing irradiation or chemotherapy. Recently, there have been a few reports of treating classic KS with paclitaxel, which has been used to treat AIDS-associated KS and post-transplant KS. We herein report a case of disseminated classic type KS in a 78-year-old Korean male patient who showed dramatic response after only two cycles of paclitaxel treatment.
Humans
;
Korea
;
Male
;
Paclitaxel
;
Sarcoma, Kaposi
;
Viruses
6.A case of neoadjuvant chemotherapy with taxol / carboplatin in advanced epithelial ovarian cancer.
Korean Journal of Obstetrics and Gynecology 2000;43(10):1874-1878
No abstract available.
Carboplatin*
;
Drug Therapy*
;
Ovarian Neoplasms*
;
Paclitaxel*
7.A Case of Squamous Cell Carcinoma of The Ovary Showing Complete Remission to Combination Chemotherapy Composed of Paclitaxel and Cisplatin.
Jin Dong JEON ; Eun Gyung CHOI ; Eun Mi JO ; Young Tae KIM ; Jae Wook KIM
Korean Journal of Obstetrics and Gynecology 2000;43(8):1492-1496
No abstract available.
Carcinoma, Squamous Cell*
;
Cisplatin*
;
Drug Therapy, Combination*
;
Female
;
Ovary*
;
Paclitaxel*
8.Stabilizing Microtubular Network Facilitates the Intracellular Growth of Orientia tsutsugamushi.
Mee Kyung KIM ; Mi Jeong KIM ; Byung Uk LIM ; Jae Seung KANG
Journal of Bacteriology and Virology 2006;36(2):51-57
Microtubule network provides many intracellular microbes with an efficient way to move within host cells. Orientia tsutsugamushi move from the cell periphery to the microtubule organizing center (MTOC) by dynein-dependent mechanism. In this study, we investigated the role of microtubule on the growth of O. tsutsugamushi. The treatment of infected cells with taxol as well as daunomycin enhanced the bacterial growth in contrast to colchicine. Immunofluorescent (IF) staining of taxol-treated cells exhibited that O. tsutsugamushi clustered tightly near the nucleus with thick bundles of microtubules, whereas dispersed in the cytoplasm in colchicine-treated cells. These results suggest that microtubule network facilitate the growth of O. tsutsugamushi.
Colchicine
;
Cytoplasm
;
Daunorubicin
;
Microtubule-Organizing Center
;
Microtubules
;
Orientia tsutsugamushi*
;
Paclitaxel
9.Carboplatin and paclitaxel as an initial treatment in patients with stage IVb cervical cancer: a report of 7 cases and a review of the literature.
Seiji MABUCHI ; Kenichirou MORISHIGE ; Takayuki ENOMOTO ; Tadashi KIMURA
Journal of Gynecologic Oncology 2010;21(2):93-96
OBJECTIVE: The aim of this study is to evaluate the efficacy of carboplatin-paclitaxel (TC) as an initial treatment in patients with the International Federation of Gynecology and Obstetrics (FIGO) stage IVb cervical cancer. METHODS: We retrospectively reviewed seven patients with stage IVb cervical cancer who have been primarily treated with TC. The activity and the toxicity were evaluated. Response rate was the main endpoint. RESULTS: Overall, the treatment of TC was well tolerated. The overall response rate was 71.4% (2 complete response, 3 partial response). Although grade 3-4 hematologic toxicities were observed in 3 out of 7 patients (42.8%), no patients experienced grade 3-4 non-hematologic toxicities. When we combined our present results with the previous reports, the overall response rate of TC is 63.6%. CONCLUSION: TC is active and well tolerated in patients FIGO stage IVb cervical cancer. This combination may be considered as an initial treatment regimen in this patient population.
Carboplatin
;
Gynecology
;
Humans
;
Obstetrics
;
Paclitaxel
;
Retrospective Studies
;
Uterine Cervical Neoplasms
10.A Case of Primary Peritoneal Serous Papillary Carcinoma.
So Hee CHEON ; Yun Jung LEE ; Soo Young HUR ; In KWEON ; Sa Jin KIM ; Eun Jung KIM ; Jeana KIM ; Sung Eun NAMKOONG ; Jong Sup PARK
Korean Journal of Obstetrics and Gynecology 2004;47(7):1427-1432
Primary peritoneal serous papillary carcinoma (PPSPC) is a rare tumor that originates from a single or multicentric foci of peritoneum. Histologically the disease resembles primary serous papillary carcinoma of the ovary, but either involves the ovarian surface microscopically only or spares the ovaries entirely. Currently PPSPC is evaluated, staged and treated in the same way as epithelial ovarian cancer. We experienced one case of primary peritoneal serous papillary carcinoma which achieved a complete remission with carboplatin and paclitaxel, and report this with brief review of the literatures.
Carboplatin
;
Carcinoma, Papillary*
;
Female
;
Ovarian Neoplasms
;
Ovary
;
Paclitaxel
;
Peritoneum